Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.

Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B.

Eur J Cancer. 2019 Jun 13;116:182-189. doi: 10.1016/j.ejca.2019.05.019. [Epub ahead of print]

PMID:
31203193
2.

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D.

ESMO Open. 2019 Feb 27;4(1):e000457. doi: 10.1136/esmoopen-2018-000457. eCollection 2019.

3.

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC.

Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28. Review.

PMID:
30954906
4.

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.

Ferrara R, Caramella C, Besse B.

JAMA Oncol. 2019 Mar 21. doi: 10.1001/jamaoncol.2019.0138. [Epub ahead of print] No abstract available.

PMID:
30896761
5.

Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

Ferrara R, Caramella C, Besse B, Champiat S.

J Thorac Oncol. 2019 Mar;14(3):328-331. doi: 10.1016/j.jtho.2018.12.011. No abstract available.

PMID:
30782378
6.

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.

J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30117-0. doi: 10.1016/j.jtho.2019.02.009. [Epub ahead of print]

PMID:
30780002
7.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT.

Eur J Cancer. 2019 Mar;109:28-35. doi: 10.1016/j.ejca.2018.11.030. Epub 2019 Jan 24.

PMID:
30685684
8.

Lessons learned from 227 biological meshes used for the surgical treatment of ventral abdominal defects.

Baldan N, Munegato G, Di Leo A, Lauro E, Morpurgo E, Pianigiani S, Briscolini D, Ferrara R, Fiscon V, Brolese A, De Manzoni G, Baldazzi G, Snidero D, Merigliano S, Ricci F, Laterza E, Merenda R, Gianesini R; NEI-Meshing Collaborative.

Hernia. 2019 Jan 19. doi: 10.1007/s10029-019-01883-2. [Epub ahead of print]

PMID:
30661179
9.

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.

Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J, Caramella C, Cassard L, Boselli L, Reiners KS, Pogge von Strandmann E, Rusakiewicz S, Ferrara R, Duchemann B, Naigeon M, Pignon JP, Besse B, Chaput N.

Eur J Cancer. 2019 Feb;108:88-96. doi: 10.1016/j.ejca.2018.12.017. Epub 2019 Jan 14.

PMID:
30648633
10.

Dark Chocolate Intake Positively Modulates Redox Status and Markers of Muscular Damage in Elite Football Athletes: A Randomized Controlled Study.

Cavarretta E, Peruzzi M, Del Vescovo R, Di Pilla F, Gobbi G, Serdoz A, Ferrara R, Schirone L, Sciarretta S, Nocella C, De Falco E, Schiavon S, Biondi-Zoccai G, Frati G, Carnevale R.

Oxid Med Cell Longev. 2018 Nov 21;2018:4061901. doi: 10.1155/2018/4061901. eCollection 2018.

11.

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.

Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R.

Eur J Cancer. 2019 Jan;106:144-159. doi: 10.1016/j.ejca.2018.11.002. Epub 2018 Dec 5. Review.

PMID:
30528799
12.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter.

Ferrara R, Susini S, Marabelle A.

Clin Cancer Res. 2019 Jun 1;25(11):3468. doi: 10.1158/1078-0432.CCR-18-3740. Epub 2018 Dec 4. No abstract available.

PMID:
30514779
13.

Hyperprogressive disease: recognizing a novel pattern to improve patient management.

Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferté C.

Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2. Review.

PMID:
30361681
14.

Uncommon immune-mediated extrahepatic manifestations of HCV infection.

Romano C, Cuomo G, Ferrara R, Del Mastro A, Esposito S, Sellitto A, Adinolfi LE.

Expert Rev Clin Immunol. 2018 Dec;14(12):1089-1099. doi: 10.1080/1744666X.2018.1538790. Epub 2018 Oct 26.

PMID:
30338718
15.

Pomegranate chitinase III: Identification of a new allergen and analysis of sensitization patterns to chitinases.

Tuppo L, Giangrieco I, Alessandri C, Ricciardi T, Rafaiani C, Ciancamerla M, Ferrara R, Zennaro D, Bernardi ML, Tamburrini M, Mari A, Ciardiello MA.

Mol Immunol. 2018 Nov;103:89-95. doi: 10.1016/j.molimm.2018.09.009. Epub 2018 Sep 19.

PMID:
30241023
16.

Intra-annual raw basal area increments (early-wood and late-wood) of Pinus nigra subsp. laricio Poiret trees from southern Italy at the pines׳ mesic to xeric distribution range.

Mazza G, Sarris D, Chiavetta U, Ferrara RM, Rana G.

Data Brief. 2018 Aug 29;20:683-685. doi: 10.1016/j.dib.2018.08.095. eCollection 2018 Oct.

17.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

PMID:
30193240
18.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD.

J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.

PMID:
30125216
19.

Do immune checkpoint inhibitors need new studies methodology?

Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, Milella M, Besse B, Tortora G, Bria E.

J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580. doi: 10.21037/jtd.2018.01.131. Review.

20.

Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study.

Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, Rapisarda F, Ferrara R, Spina E, Arcoraci V.

Front Pharmacol. 2018 Apr 11;9:350. doi: 10.3389/fphar.2018.00350. eCollection 2018.

21.

Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting.

Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, Alecci U, Scoglio R, Magliozzo F, Torrisi SE, Vancheri C, Vitulo P, Fantaci G, Ferrajolo C, Cazzola M, Cricelli C, Caputi AP, Trifirò G.

NPJ Prim Care Respir Med. 2018 Mar 23;28(1):10. doi: 10.1038/s41533-018-0077-7.

22.

A polydnavirus-encoded ANK protein has a negative impact on steroidogenesis and development.

Ignesti M, Ferrara R, Romani P, Valzania L, Serafini G, Pennacchio F, Cavaliere V, Gargiulo G.

Insect Biochem Mol Biol. 2018 Apr;95:26-32. doi: 10.1016/j.ibmb.2018.03.003. Epub 2018 Mar 17.

PMID:
29559251
23.

Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study.

Rosati G, Pinto C, Di Fabio F, Chiara S, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrara R, Antonuzzo L, Adua D, Racca P, Bilancia D, Benincasa E, Stroppolo ME, Di Costanzo F.

J Geriatr Oncol. 2018 May;9(3):243-248. doi: 10.1016/j.jgo.2018.01.009. Epub 2018 Feb 9.

24.

Progress in the Management of Advanced Thoracic Malignancies in 2017.

Ferrara R, Mezquita L, Besse B.

J Thorac Oncol. 2018 Mar;13(3):301-322. doi: 10.1016/j.jtho.2018.01.002. Epub 2018 Jan 11. Review.

25.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

26.

Private States, Quantum Data Hiding, and the Swapping of Perfect Secrecy.

Christandl M, Ferrara R.

Phys Rev Lett. 2017 Dec 1;119(22):220506. doi: 10.1103/PhysRevLett.119.220506. Epub 2017 Nov 30.

PMID:
29286800
27.

The development of PARP as a successful target for cancer therapy.

Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.

Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26. Review.

PMID:
29260919
28.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
29.

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.

Ferrara R, Auger N, Auclin E, Besse B.

J Thorac Oncol. 2018 Jan;13(1):27-45. doi: 10.1016/j.jtho.2017.10.021. Epub 2017 Nov 8. Review.

30.

The neonicotinoid insecticide Clothianidin adversely affects immune signaling in a human cell line.

Di Prisco G, Iannaccone M, Ianniello F, Ferrara R, Caprio E, Pennacchio F, Capparelli R.

Sci Rep. 2017 Oct 18;7(1):13446. doi: 10.1038/s41598-017-13171-z.

31.

Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?

Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B.

Cancer Treat Rev. 2017 Nov;60:60-68. doi: 10.1016/j.ctrv.2017.08.003. Epub 2017 Aug 24. Review.

32.

Diagnosing allergic sensitizations in the third millennium: why clinicians should know allergen molecule structures.

Alessandri C, Ferrara R, Bernardi ML, Zennaro D, Tuppo L, Giangrieco I, Tamburrini M, Mari A, Ciardiello MA.

Clin Transl Allergy. 2017 Jul 17;7:21. doi: 10.1186/s13601-017-0158-7. eCollection 2017. Review.

33.

The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score.

Andracco R, Irace R, Zaccara E, Vettori S, Maglione W, Riccardi A, Pignataro F, Ferrara R, Sambataro D, Sambataro G, Vitali C, Valentini G, Del Papa N.

Arthritis Res Ther. 2017 Jun 13;19(1):133. doi: 10.1186/s13075-017-1354-5.

34.

Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015.

Ferrara R, Ientile V, Arcoraci V, Ferrajolo C, Piccinni C, Fontana A, Benvenga S, Trifirò G.

Endocrine. 2017 Oct;58(1):143-152. doi: 10.1007/s12020-017-1242-4. Epub 2017 Feb 2.

PMID:
28155170
35.

Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report.

Ciccarese C, Ferrara R, Fantinel E, Zecchetto C, Simionato F, Grego E, Ortolani S, Caccese M, Bimbatti D, Cingarlini S, Brunelli M, Andreini A, Tortora G, Massari F.

Future Sci OA. 2015 Nov 1;1(4):FSO29. doi: 10.4155/fso.15.27. eCollection 2015 Nov.

36.

The pressure reduction coefficient: A new parameter to assess aneurysmal blood stasis induced by flow diverters/disruptors.

Gascou G, Ferrara R, Ambard D, Sanchez M, Lobotesis K, Jourdan F, Costalat V.

Interv Neuroradiol. 2017 Feb;23(1):41-46. doi: 10.1177/1591019916673219. Epub 2016 Dec 5.

37.

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.

Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, Pilotto S, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A.

J Pathol. 2017 Mar;241(4):488-500. doi: 10.1002/path.4853. Epub 2016 Dec 29.

38.

Autism Spectrum Disorder and intact executive functioning.

Ferrara R, Ansermet F, Massoni F, Petrone L, Onofri E, Ricci P, Archer T, Ricci S.

Clin Ter. 2016 Sep-Oct;167(5):e96-e101. doi: 10.7417/CT.2016.1951.

PMID:
27845486
39.

Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.

Pinto C, Di Fabio F, Rosati G, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrari D, Lo Re G, Rosti G, Tralongo P, Ferrara R, Alabiso O, Chiara S, Ianniello GP, Frassoldati A, Bilancia D, Campanella GA, Signorelli C, Racca P, Benincasa E, Stroppolo ME, Di Costanzo F.

Cancer Med. 2016 Nov;5(11):3272-3281. doi: 10.1002/cam4.888. Epub 2016 Oct 17.

40.

Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.

Caccese M, Ferrara R, Pilotto S, Carbognin L, Grizzi G, Caliò A, Brunelli M, Cuppone F, Petraglia S, Scarpa A, Tortora G, Bria E.

Expert Opin Pharmacother. 2016 Dec;17(17):2253-2266. Epub 2016 Oct 8. Review.

PMID:
27682212
41.

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.

Peretti U, Ferrara R, Pilotto S, Kinspergher S, Caccese M, Santo A, Brunelli M, Caliò A, Carbognin L, Sperduti I, Garassino M, Chilosi M, Scarpa A, Tortora G, Bria E.

Respir Res. 2016 Aug 25;17(1):105. doi: 10.1186/s12931-016-0422-8.

42.

A mutualistic symbiosis between a parasitic mite and a pathogenic virus undermines honey bee immunity and health.

Di Prisco G, Annoscia D, Margiotta M, Ferrara R, Varricchio P, Zanni V, Caprio E, Nazzi F, Pennacchio F.

Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3203-8. doi: 10.1073/pnas.1523515113. Epub 2016 Mar 7.

43.

Tubulin inhibitors in non-small cell lung cancer: looking back and forward.

Ferrara R, Pilotto S, Peretti U, Caccese M, Kinspergher S, Carbognin L, Karachaliou N, Rosell R, Tortora G, Bria E.

Expert Opin Pharmacother. 2016 Jun;17(8):1113-29. doi: 10.1517/14656566.2016.1157581. Epub 2016 Mar 10. Review.

PMID:
26898217
44.

The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.

Calvetti L, Pilotto S, Carbognin L, Ferrara R, Caccese M, Tortora G, Bria E.

Expert Opin Biol Ther. 2015;15(9):1359-70. doi: 10.1517/14712598.2015.1071350. Epub 2015 Jul 20. Review.

PMID:
26190526
45.

An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.

Pilotto S, Novello S, Peretti U, Kinspergher S, Ciuffreda L, Milella M, Carbognin L, Vavalà T, Ferrara R, Caccese M, Tortora G, Bria E.

Expert Opin Investig Drugs. 2015;24(9):1143-61. doi: 10.1517/13543784.2015.1056341. Epub 2015 Jun 12. Review.

PMID:
26065529
46.

Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.

Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg SA, Jensen BM, Quaak S, Akkerdaas JH, Blom L, Asturias J, Bindslev-Jensen C, Bernardi ML, Clausen M, Ferrara R, Hauer M, Heyse J, Kopp S, Kowalski ML, Lewandowska-Polak A, Linhart B, Maderegger B, Maillere B, Mari A, Martinez A, Mills EN, Neubauer A, Nicoletti C, Papadopoulos NG, Portoles A, Ranta-Panula V, Santos-Magadan S, Schnoor HJ, Sigurdardottir ST, Stahl-Skov P, Stavroulakis G, Stegfellner G, Vázquez-Cortés S, Witten M, Stolz F, Poulsen LK, Fernandez-Rivas M, Valenta R, van Ree R.

Int Arch Allergy Immunol. 2015;166(1):41-51. doi: 10.1159/000371657. Epub 2015 Feb 28.

47.

Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011.

Italiano D, Capuano A, Alibrandi A, Ferrara R, Cannata A, Trifirò G, Sultana J, Ferrajolo C, Tari M, Tari DU, Perrotta M, Pagliaro C, Rafaniello C, Spina E, Arcoraci V.

Br J Clin Pharmacol. 2015 Jun;79(6):1010-9. doi: 10.1111/bcp.12577.

48.

Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?

Pilotto S, Kinspergher S, Peretti U, Calio A, Carbognin L, Ferrara R, Brunelli M, Chilosi M, Tortora G, Bria E.

Anticancer Agents Med Chem. 2015;15(3):307-13. Review.

PMID:
25382117
49.

Effect of an educational program in primary care: the case of lipid control in cardio-cerebrovascular prevention.

Arcoraci V, Santoni L, Ferrara R, Furneri G, Cannata A, Sultana J, Moretti S, Di Luccio A, Tari DU, Pagliaro C, Corrao S, Tari M.

Int J Immunopathol Pharmacol. 2014 Jul-Sep;27(3):351-63.

PMID:
25280026
50.

Environmental performances of Sardinian dairy sheep production systems at different input levels.

Vagnoni E, Franca A, Breedveld L, Porqueddu C, Ferrara R, Duce P.

Sci Total Environ. 2015 Jan 1;502:354-61. doi: 10.1016/j.scitotenv.2014.09.020. Epub 2014 Sep 29.

PMID:
25265396

Supplemental Content

Loading ...
Support Center